eMedicine Specialties > Emergency Medicine > Psychosocial

Panic Disorders

Author: Michael C Plewa, MD, Research Coordinator, Consulting Staff, Department of Emergency Medicine, Lucas County Emergency Physicians, Inc, and Saint Vincent Mercy Medical Center
Contributor Information and Disclosures

Updated: May 7, 2009

Introduction

Background

An understanding of panic disorder (PD) is important for emergency physicians because patients with panic disorder frequently present to the emergency department (ED) with various somatic complaints. As many as 70% of persons with panic disorder are unrecognized as having this condition, and few individuals with panic disorder are referred to mental health professionals.

Persons with panic disorder have a 4-fold higher risk of alcohol abuse and an 18-fold higher risk of suicide than the general population (although some studies suggest that panic disorder itself is not a risk factor for suicide in the absence of other risks, such as affective disorders, substance abuse, eating disorders, and personality disorders).1 Serious medical problems, such as asthma or cardiac dysrhythmia, or metabolic disturbances, such as hypoglycemia, hypoxia, and thyroid storm, can mimic panic attack.

Following exclusion of somatic disease and other psychiatric disorders, confirmation of the diagnosis with a brief mental status screening examination and initiation of appropriate treatment and referral is time- and cost-effective in these patients who have high rates of medical resource use.

See Medscape's Anxiety Disorders Resource Center for more information.

Pathophysiology

Panic disorder appears to be a genetically inherited neurochemical dysfunction that may involve autonomic imbalance; allelic polymorphism of the catechol-O-methyltransferase (COMT) gene; increased adenosine receptor function; increased cortisol;2 diminished benzodiazepine receptor function; and disturbances in serotonin,3 norepinephrine, gamma-aminobutyric acid, dopamine, cholecystokinin, and interleukin-1-beta.4 Some theorize that panic disorder may represent a state of chronic hyperventilation and carbon dioxide receptor hypersensitivity.5 Some epileptic patients have panic as a manifestation of their seizures.

Positron emission tomography (PET) scanning has demonstrated increased flow in the right parahippocampal region and reduced serotonin type 1A receptor binding in the anterior and posterior cingulate and raphe of patients with panic disorder.3 Magnetic resonance imaging (MRI) has demonstrated smaller temporal lobe volume despite normal hippocampal volume in these patients.6

In experimental settings, symptoms can be elicited in people with panic disorder by hyperventilation, inhalation of carbon dioxide, caffeine consumption, or intravenous infusions of sodium lactate, cholecystokinin, isoproterenol, or flumazenil.5

The cognitive theory regarding panic is that these patients have a heightened sensitivity to internal autonomic cues (eg, tachycardia).

Panic disorder is associated with depression, obsessive-compulsive disorder, restless leg syndrome,7 fatigue,8 specific phobias, social phobia, agoraphobia (ie, fear of being unsafe in public settings), irritable bowel syndrome, migraine, mitral valve prolapse, and alcohol and drug abuse. Individuals with panic disorder also have lower oxygen consumption and exercise tolerance than the general population.9 They also have reduced heart rate variability and increased QT variability on electrocardiography and may have a higher risk of cardiovascular disease and sudden death.10

Frequency

United States

Panic disorder has an approximate 1-5% prevalence in the population.

International

Prevalence is similar to that in the United States.

Mortality/Morbidity

  • Panic disorder can lead to a significant hindrance in lifestyle (many people with agoraphobia are unable to travel alone or be in crowds, malls, or on public transportation), including problems with employment, depression, substance abuse, and suicide.
  • Panic disorder is present in 30% of patients with chest pain and normal findings on angiography, 5-40% of persons with asthma, 15% of patients with headache, 20% of patients with epilepsy, 8-15% of individuals in alcohol treatment programs, and 10% of patients in primary care settings.
  • Panic disorder may be associated with a higher risk of cardiovascular disease and sudden death.
  • A variant of panic disorder unrelated to fear (nonfearful panic disorder [NFPD]) is associated with high rates medical resource use (32-41% of patients with panic disorder seeking treatment for chest pain) and poor prognosis.11

Sex

  • Prevalence is higher in females than in males, with a female-to-male ratio of approximately 2:1.
  • Panic is more common in women who have never been pregnant and during the postpartum period, but it is less common during pregnancy.

Age

  • Although panic can occur in people at any age, the average age of onset, as with most anxiety disorders, is in the third decade of life, and it usually occurs between the ages of 18 and 45 years.
  • Panic disorder has a bimodal age of onset, with patients with late-onset panic disorder having less mental health use, lower comorbidity and hypochondriasis, and better coping behavior.12

Clinical

History

  • Patients who experience panic attack report a spontaneous sudden onset of fear or discomfort, typically reaching a peak within 10 minutes.
  • Attacks are associated with a constellation of systemic symptoms, including the following (4 or more of these are needed for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IV] criteria):
    • Palpitations, pounding heart, or accelerated heart rate
    • Sweating
    • Trembling or shaking
    • Shortness of breath or feeling of smothering
    • Choking sensation
    • Chest pain or discomfort
    • Nausea or abdominal distress
    • Feeling dizzy, unsteady, lightheaded, or faint
    • Derealization (ie, feeling of unreality) or depersonalization (ie, being detached from oneself)
    • Fear of losing control or going crazy
    • Fear of dying
    • Paresthesias (ie, numbness or tingling sensations)
    • Chills or hot flashes
  • During the episode, patients have the urge to flee or escape and have a sense of impending doom (as though they are dying from a heart attack or suffocation).
  • Other symptoms may include headache, cold hands, diarrhea, insomnia, fatigue, intrusive thoughts, and ruminations.
  • Patients with panic disorder have recurring episodes of panic, with the fear of recurrent attack resulting in significant behavioral changes (eg, avoiding situations or locations) and worry about the implications of the attack or its consequences (eg, losing control, going crazy, dying).
  • Panic disorder may result in changes in personality traits, characterized by the patient becoming more passive, dependent, or withdrawn.
  • DSM-IV criteria include 4 or more attacks in a 4-week period or 1 or more attacks followed by at least 1 month of fear of another.
  • Agoraphobia, present in 30% of persons with PD, establishes the diagnosis.
  • Assess precipitating events, suicidal ideation or plan, phobias, agoraphobia, and obsessive-compulsive behavior.
  • Exclude involvement of alcohol, illicit drugs (eg, cocaine, amphetamine, phencyclidine, amyl nitrate, lysergic acid diethylamide [LSD], yohimbine, 3,4-methylenedioxymethamphetamine [MDMA, ecstasy]), cannabis, and medications (eg, caffeine, theophylline, sympathomimetics, anticholinergics).
  • Consider symptomatology of other medical disorders, which may manifest with anxiety as a primary symptom.
    • Angina and myocardial infarction (eg, dyspnea, chest pain, palpitations, diaphoresis)
    • Cardiac dysrhythmias (eg, palpitations, dyspnea, syncope)
    • Mitral valve prolapse
    • Pulmonary embolus (eg, dyspnea, hyperpnea, chest pain)
    • Asthma (eg, dyspnea, wheezing)
    • Hyperthyroidism (eg, palpitations, diaphoresis, tachycardia, heat intolerance)
    • Hypoglycemia
    • Pheochromocytoma (eg, headache, diaphoresis, hypertension)
    • Hypoparathyroidism (eg, muscle cramps, paresthesias)
    • Transient ischemic attacks (TIAs)
    • Seizure disorders
  • Consider other mental illnesses that may result in panic attacks, including schizophrenia, manic disorder, depressive disorder, posttraumatic stress disorder, phobic disorders, and somatization disorder.
  • Assess family history of panic or other psychiatric illness.

Physical

  • The patient may have an anxious appearance.
  • Tachycardia and tachypnea are common; blood pressure and temperature may be within the reference range.
  • Cool clammy skin may be observed.
  • Hyperventilation may be difficult to detect by observing breathing because respiratory rate and tidal volume may appear normal.
    • Patients may have frequent sighs or difficulty with breath holding.
    • Reproduction of symptoms with overbreathing is unreliable.
    • Chvostek sign, Trousseau sign, or overt carpopedal spasm may be present.
  • Mental status screening is essential for diagnosis. Standardized examinations include the following:
    • Primary Care Evaluation of Mental Disorders (PRIME-MD)
    • Mobility Inventory for Agoraphobia (MIA)
    • The Agoraphobia Cognitions Questionnaire (ACA)
    • The Body Sensations Questionnaire (BSQ)
  • The remaining examination findings are typically normal in panic disorder. However, remember that panic disorder is largely a diagnosis of exclusion, and attention should be focused on the exclusion of other disorders.

Causes

Triggers of panic can include the following:

  • Injury (eg, accidents, surgery)
  • Illness
  • Interpersonal conflict or loss
  • Use of cannabis (can be associated with panic attacks, perhaps because of breath-holding)13
  • Use of stimulants, such as caffeine, decongestants, cocaine, and sympathomimetics (eg, amphetamine, MDMA)14
  • Certain settings, such as stores and public transportation (especially in patients with agoraphobia)

More on Panic Disorders

Overview: Panic Disorders
Differential Diagnoses & Workup: Panic Disorders
Treatment & Medication: Panic Disorders
Follow-up: Panic Disorders
References
Further Reading

References

  1. Warshaw MG, Dolan RT, Keller MB. Suicidal behavior in patients with current or past panic disorder: five years of prospective data from the Harvard/Brown Anxiety Research Program. Am J Psychiatry. Nov 2000;157(11):1876-8. [Medline].

  2. Wedekind D, Bandelow B, Broocks A, et al. Salivary, total plasma and plasma free cortisol in panic disorder. J Neural Transm. 2000;107(7):831-7. [Medline].

  3. Neumeister A, Bain E, Nugent AC. Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci. Jan 21 2004;24(3):589-91. [Medline].

  4. Johnson MR, Lydiard RB, Ballenger JC. Panic disorder. Pathophysiology and drug treatment. Drugs. Mar 1995;49(3):328-44. [Medline].

  5. Dratcu L. Panic, hyperventilation and perpetuation of anxiety. Prog Neuropsychopharmacol Biol Psychiatry. Oct 2000;24(7):1069-89. [Medline].

  6. Vythilingam M, Anderson ER, Goddard A, et al. Temporal lobe volume in panic disorder--a quantitative magnetic resonance imaging study. Psychiatry Res. Aug 28 2000;99(2):75-82. [Medline].

  7. Lee HB, Hening WA, Allen RP, Kalaydjian AE, Earley CJ, Eaton WW, et al. Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community. J Neuropsychiatry Clin Neurosci. Winter 2008;20(1):101-5. [Medline].

  8. Kaiya H, Sugaya N, Iwasa R, Tochigi M. Characteristics of fatigue in panic disorder patients. Psychiatry Clin Neurosci. Apr 2008;62(2):234-7. [Medline].

  9. Schmidt NB, Lerew DR, Santiago H, et al. Effects of heart-rate feedback on estimated cardiovascular fitness in patients with panic disorder. Depress Anxiety. 2000;12(2):59-66. [Medline].

  10. Sullivan GM, Kent JM, Kleber M. Effects of hyperventilation on heart rate and QT variability in panic disorder pre- and post-treatment. Psychiatry Res. Jan 30 2004;125(1):29-39. [Medline].

  11. Fleet RP, Martel JP, Lavoie KL, et al. Non-fearful panic disorder: a variant of panic in medical patients?. Psychosomatics. Jul-Aug 2000;41(4):311-20. [Medline].

  12. Katerndahl DA, Talamantes M. A comparison of persons with early-versus late-onset panic attacks. J Clin Psychiatry. Jun 2000;61(6):422-7. [Medline].

  13. Dannon PN, Lowengrub K, Amiaz R. Comorbid cannabis use and panic disorder: short term and long term follow-up study. Hum Psychopharmacol. Mar 2004;19(2):97-101. [Medline].

  14. Schifano F, Di Furia L, Forza G, et al. MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Depend. Sep 1 1998;52(1):85-90. [Medline].

  15. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1998;59 Suppl 8:47-54. [Medline].

  16. Baldwin DS, Birtwistle J. The side effect burden associated with drug treatment of panic disorder. J Clin Psychiatry. 1998;59 Suppl 8:39-44; discussion 45-6. [Medline].

  17. Bandelow B, Behnke K, Lenoir S. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry. Mar 2004;65(3):405-13. [Medline].

  18. Bakker A, van Balkom AJ, van Dyck R. Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia. Int Clin Psychopharmacol. Aug 2000;15 Suppl 2:S25-30. [Medline].

  19. Cloos JM. The treatment of panic disorder. Curr Opin Psychiatry. Jan 2005;18(1):45-50. [Medline].

  20. [Best Evidence] Furukawa TA, Watanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br J Psychiatry. Apr 2006;188:305-12. [Medline].

  21. Gomez-Caminero A, Blumentals WA, Russo LJ. Does panic disorder increase the risk of coronary heart disease? A cohort study of a national managed care database. Psychosom Med. Sep-Oct 2005;67(5):688-91. [Medline].

  22. Fleet R, Lesperance F, Arsenault A, et al. Myocardial perfusion study of panic attacks in patients with coronary artery disease. Am J Cardiol. Oct 15 2005;96(8):1064-8. [Medline].

  23. Clum GA, Clum GA, Surls R. A meta-analysis of treatments for panic disorder. J Consult Clin Psychol. Apr 1993;61(2):317-26. [Medline].

  24. Davidson JR. The long-term treatment of panic disorder. J Clin Psychiatry. 1998;59 Suppl 8:17-21; discussion 22-3. [Medline].

  25. den Boer JA. Pharmacotherapy of panic disorder: differential efficacy from a clinical viewpoint. J Clin Psychiatry. 1998;59 Suppl 8:30-6; discussion 37-8. [Medline].

  26. Fleet RP, Dupuis G, Marchand A, et al. Panic disorder in emergency department chest pain patients: prevalence, comorbidity, suicidal ideation, and physician recognition. Am J Med. Oct 1996;101(4):371-80. [Medline].

  27. Fleet RP, Marchand A, Dupuis G, et al. Comparing emergency department and psychiatric setting patients with panic disorder. Psychosomatics. Nov-Dec 1998;39(6):512-8. [Medline].

  28. Hofmann SG, Spiegel DA. Panic control treatment and its applications. J Psychother Pract Res. 1999;8(1):3-11. [Medline].

  29. Katerndahl DA. Panic attacks and panic disorder. J Fam Pract. Sep 1996;43(3):275-82. [Medline].

  30. Kjernisted K, McIntosh D. Venlafaxine extended release (XR) in the treatment of panic disorder. Ther Clin Risk Manag. Mar 2007;3(1):59-69. [Medline].

  31. Loerch B, Graf-Morgenstern M, Hautzinger M, et al. Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. Br J Psychiatry. Mar 1999;174:205-12. [Medline].

  32. Margraf J, Barlow DH, Clark DM, et al. Psychological treatment of panic: work in progress on outcome, active ingredients, and follow-up. Behav Res Ther. Jan 1993;31(1):1-8. [Medline].

  33. Michelson D, Pollack M, Lydiard RB, et al. Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. Br J Psychiatry. Mar 1999;174:213-8. [Medline].

  34. Michelson LK, Marchione K. Behavioral, cognitive, and pharmacological treatments of panic disorder with agoraphobia: critique and synthesis. J Consult Clin Psychol. Feb 1991;59(1):100-14. [Medline].

  35. Otto MW, Pollack MH, Maki KM. Empirically supported treatments for panic disorder: costs, benefits, and stepped care. J Consult Clin Psychol. Aug 2000;68(4):556-63. [Medline].

  36. Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry. Sep 1998;155(9):1189-95. [Medline].

  37. Rickels K, Schweizer E. Panic disorder: long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol. Dec 1998;18(6 Suppl 2):12S-18S. [Medline].

  38. Roy-Byrne P, Stein M, Bystrisky A, et al. Pharmacotherapy of panic disorder: proposed guidelines for the family physician. J Am Board Fam Pract. Jul-Aug 1998;11(4):282-90. [Medline].

  39. Roy-Byrne PP. Integrated treatment of panic disorder. Am J Med. Jan 24 1992;92(1A):S. [Medline].

  40. Roy-Byrne PP, Stein MB, Russo J, et al. Panic disorder in the primary care setting: comorbidity, disability, service utilization, and treatment. J Clin Psychiatry. Jul 1999;60(7):492-9; quiz 500. [Medline].

Further Reading

Clinical guidelines

Practice guideline for the treatment of patients with panic disorder, second edition. Work Group on Panic Disorder. American Psychiatric Association. 2009

Keywords

panic disorder, panic attack, panic attacks, anxiety attack, mood disorder, nonfearful panic disorder, NFPD, anxiety disorders, agoraphobia, psychiatric disorder, PD

Contributor Information and Disclosures

Author

Michael C Plewa, MD, Research Coordinator, Consulting Staff, Department of Emergency Medicine, Lucas County Emergency Physicians, Inc, and Saint Vincent Mercy Medical Center
Michael C Plewa, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, Physicians for Social Responsibility, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Medical Editor

Samuel M Keim, MD, Associate Professor, Department of Emergency Medicine, University of Arizona College of Medicine
Samuel M Keim, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Public Health Association, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Robert Harwood, MD, MPH, FACEP, FAAEM, Program Director, Department of Emergency Medicine, Advocate Christ Medical Center; Assistant Professor, Department of Emergency Medicine, University of Illinois at Chicago College of Medicine
Robert Harwood, MD, MPH, FACEP, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, Council of Emergency Medicine Residency Directors, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Jonathan Adler, MD, Attending Physician, Department of Emergency Medicine, Massachusetts General Hospital; Division of Emergency Medicine, Harvard Medical School
Jonathan Adler, MD is a member of the following medical societies: American Academy of Emergency Medicine and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.